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OBJECTIVES We sought to address the issues of safety, feasibility and clinical impact of noninvasive
diagnosis of coronary vasospasm (CVS).
BACKGROUND The safety of ergonovine provocation for CVS performed outside the catheterization
laboratory has been questioned.
METHODS We performed a retrospective analysis of the results of bedside ergonovine provocation testing
by monitoring left ventricular regional wall motion abnormalities (RWMAs) using two-
dimensional echocardiography (Erg Echo).
RESULTS After confirming that there was no significant epicardial coronary stenosis, Erg Echo was
performed on 1,372 patients from July 1991 to December 1997. Ergonovine echocardiogra-
phy was terminated prematurely in 13 patients (0.9%) because of limitations caused by side
effects unrelated to myocardial ischemia. Among 1,359 completed tests, 31% (n 5 421) showed
positive results, with development of RWMAs in 412 tests (98%) or ST displacement in
electrocardiograms of nine tests (2%). Arrhythmias developed in 1.9% (26/1,372), including
transient ventricular tachycardia (n 5 2) and atrioventricular block (n 5 4), which were promptly
reversed with nitroglycerin. There was no mortality or development of myocardial infarction.
Based on the angiographic criteria of 218 patients, the sensitivity and specificity of Erg Echo for
the diagnosis of CVS were 93% and 91%, respectively. Since 1994, Erg Echo has become a more
popular diagnostic method than invasive spasm provocation testing in the catheterization
laboratory and has comprised more than 95% of all spasm provocation tests during the last three
years. In the outpatient clinic, 453 patients underwent Erg Echo safely.
CONCLUSIONS Although this is a retrospective study in a single center, we believe that Erg Echo is highly
feasible, accurate and safe for the diagnosis of CVS and can replace invasive angiographic
spasm provocation testing in the catheterization laboratory. (J Am Coll Cardiol 2000;35:
1850–6) © 2000 by the American College of Cardiology
Coronary vasospasm (CVS) is a reversible constriction of
epicardial coronary arteries, evoking acute myocardial isch-
emia (1). It has been considered as one of the major
mechanisms causing dynamic stenosis of the coronary artery
and has also been documented to be a contributor to the
development of effort-induced angina, unstable angina,
acute myocardial infarction and sudden cardiac death, as
well as variant angina (2–4).
See page 1857
Classically, CVS has been diagnosed by an invasive
provocative procedure during diagnostic coronary angiogra-
phy (5). Considering that various noninvasive diagnostic
tests for significant fixed atherosclerotic stenosis of epicar-
dial coronary arteries (exercise electrocardiogram, stress
echocardiography and nuclear tests) are being used routinely
in daily practice, it would be very useful to have a reliable,
noninvasive and safe diagnostic method to document CVS.
However, some case reports of the development of fatal
arrhythmias or acute myocardial infarctions during spasm
provocation testing in the catheterization laboratory have
discouraged physicians from attempting to establish a non-
invasive diagnostic method (6–8).
The development of regional wall motion abnormalities
(RWMAs) of the left ventricle is known to be an early
phenomenon during myocardial ischemia (9), and many
modalities of stress echocardiography for noninvasive diag-
nosis of significant fixed atherosclerotic stenosis of major
epicardial coronary arteries have been established during the
last two decades (10,11). Distante and colleagues (12,13)
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reported that development of RWMAs due to CVS could
be detected by echocardiography before any ECG change
during spasm provocation testing in the catheterization
laboratory. Several years ago, we proposed that a bedside
ergonovine provocation test with two-dimensional echocar-
diographic monitoring of left ventricular wall motion (er-
gonovine echocardiography, Erg Echo) could be used as a
reliable noninvasive diagnostic method for CVS in patients
with near-normal angiographic findings (14,15). Our idea
was to detect the development of RWMAs, which are
sensitive and early markers of myocardial ischemia, and
thereby contribute to the safety of the procedure by allowing
us to terminate an ischemic cascade earlier during spasm
provocation testing at bedside rather than in the catheter-
ization room. However, the safety of ergonovine provoca-
tion for CVS performed outside the catheterization labora-
tory has been questioned (8), and the real clinical impact of
this noninvasive testing in routine practice has not been
analyzed. The purpose of this study was to address the issues
of feasibility, safety and clinical impact of Erg Echo for
noninvasive diagnosis of CVS.
METHODS
We reviewed the data for spasm provocation testing per-
formed in the echocardiography or catheterization labora-
tories at our institution from 1990 to December 1997.
Erg Echo (14,15). An intravenous line was placed in the
upper arm, and noninvasive blood pressure and lead II of the
electrocardiogram (ECG) were monitored during the entire
procedure. Figure 1 is a diagram showing the protocol of
Erg Echo. Bolus injections of ergonovine maleate (50 mg)
were administered intravenously at 5-min intervals until a
positive response was obtained or a total dose of 0.35 mg
was reached. The 12-lead ECG was recorded after each
ergonovine injection, and left ventricular wall motion was
monitored continuously. Regional wall motion was analyzed
by two experienced echocardiography specialists (J.K.S.,
D.H.K.) using a side-by-side continuous cine-loop display
method with a commercially available quad system. Re-
gional wall motion abnormalities were generally used to
describe any segment graded dyskinetic, akinetic or hypo-
kinetic. Regional wall motion was assessed according to the
recommendations of the American Society of Echocardiog-
raphy with a 16-segment model (16), and the territory of
CVS was diagnosed based on the segments showing wall
motion abnormalities (Fig. 2, A and B).
Positive criteria for the test included the appearance of
transient ST segment elevation or depression .0.1 mV at
0.08 s after the J point (ECG criteria) or reversible
RWMAs by two-dimensional echocardiography (echocar-
diographic criteria). The criteria for terminating the test
were as follows: positive response defined as ECG or
echocardiographic criteria, total cumulative dose of 0.35 mg
ergonovine, or development of significant arrhythmia or
changes in vital signs (systolic blood pressure .200 mm Hg
or ,90 mm Hg). An intravenous bolus injection of nitro-
glycerin (0.25 mg) and sublingual nitroglycerin (0.6 mg) was
given as soon as a positive response (ECG or echocardio-
graphic criteria) was detected or at the end of a test with a
negative response. Sublingual nifedipine (10 mg) was also
administered for possible delayed effects of ergonovine. The
administration of these drugs was repeated as needed.
In a spasm provocation test, the possibility of significant
fixed atherosclerotic stenosis of major coronary arteries was
usually ruled out by treadmill testing or a dipyridamole-
thallium-201 myocardial perfusion scan. For some patients,
invasive coronary angiography was done to rule out the
Abbreviations and Acronyms
CVS 5 coronary vasospasm
ECG 5 electrocardiogram
Erg Echo 5 ergonovine echocardiography
RWMAs 5 regional wall motion abnormalities
Figure 1. Protocol of ergonovine echocardiography. ECG 5 electrocardiogram.
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significant fixed lesion. All cardioactive drugs (beta-adrenergic
blocking agents, calcium channel blocker and nitrates) were
discontinued for at least five half-lives, but nitroglycerin was
administered sublingually as necessary. Resting hypertension
was usually controlled by using an angiotensin converting
enzyme inhibitor; blood pressure .150/90 mm Hg was an
absolute contraindication for the test.
Diagnostic coronary angiography and invasive spasm
provocation. Coronary angiography was performed ac-
cording to the conventional Judkins or Sones technique.
Patients with a significant fixed atherosclerotic stenosis
($50% lumen diameter) were excluded from the spasm
provocation test. A pharmacologic provocation test for CVS
was done using intravenous (5), intracoronary ergonovine
(17) or intracoronary acetylcholine (18), according to the
methods described elsewhere. The appearance of total or
subtotal occlusion of a major coronary artery associated with
ST segment elevation or depression on the ECG or typical
chest pain, or both, was considered to be a manifestation of
CVS (Fig. 2, C and D).
Statistical analysis. Results of analyses are expressed as
mean 6 standard deviation. The overall sensitivity and
specificity of Erg Echo were calculated from 2 3 2 tables.
Categorical variables were analyzed with chi-square, and a
p value ,0.05 was considered as statistically significant.
RESULTS
Ergonovine echocardiography was performed on 1,372 pa-
tients from July 1991 to December 1997. There were 908 men
and 464 women. The mean age was 53 6 10 years (19–80).
Before Erg Echo, significant atherosclerotic fixed disease was
ruled out by negative results in exercise electrocardiographic
tests in 46% of the patients, normal myocardial perfusion scan
in 32% and normal coronary angiograms in 22%.
Ergonovine echocardiography was performed for differ-
ential diagnosis of chest pain syndromes in the majority of
cases (91%). In 7%, the assessment of the efficacy of the
prescribed medication for patients with documented CVS
indicated the test, and in 2% the test was performed to
monitor the activity of the spasm during clinical follow-up.
Figure 3 shows the clinical impression of attending physi-
cians before the testing. Variant angina was the most
frequent referral diagnosis for the test (42%); however, Erg
Echo was also requested for patients with a clinical diagno-
sis of non-ischemic chest pain, unstable angina, effort
angina, myocardial infarction and aborted (successfully re-
suscitated) sudden cardiac death.
Feasibility, diagnostic validity and safety of Erg Echo.
Ergonovine echocardiography was terminated prematurely
in 13 patients (0.9%) because of limiting side effects during
the procedure, without any evidence of myocardial ischemia.
These side effects consisted of hypertension (systolic blood
pressure .200 mm Hg) in five patients, hypotension
(systolic blood pressure ,90 mm Hg) in two patients,
nausea with vomiting in three patients, headache in two
patients and back pain in one patient. All the side effects in
these patients with incomplete tests were reversed promptly
with intravenous nitroglycerin.
Figure 2. Representative example of ergonovine echocardiography
(A and B) and invasive spasm provocation testing during diagnostic
coronary angiography (C and D) in a 47-year-old man. Left ventric-
ular wall motion at end-systole recorded in the apical two-chamber
view was demonstrated (A and B). Compared with the basal status
(A), prominent loss of systolic myocardial thickening in the inferior
wall developed with an ergonovine dose of 0.15 mg (B, white arrow),
which was compatible with myocardial ischemia due to coronary
artery spasm in the right coronary artery territory. Coronary angio-
gram taken three days later revealed no significant fixed disease.
Intravenous injection of ergonovine (E1) provoked total occlusion of
the distal right coronary artery (C), and the angiogram after injection
of nitroglycerin (N) showed completely normal right coronary artery
and relief of total occlusion (D).
Figure 3. Clinical diagnosis before ergonovine echocardiography.
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Among 1,359 completed tests, 421 tests (31%) showed
the positive response, while 938 tests were negative. Of 421
positive tests, 412 tests (98%) showed obvious RWMAs in
two-dimensional echocardiography (echocardiographic cri-
teria); in the remaining nine tests, ST segment displacement
(elevation in six and depression in three) in the 12-lead
ECG was the only criterium for positive response attribut-
able to poor echocardiographic window (ECG criteria). The
involved territories of the CVS, based on the echocardio-
graphic criteria, were the left anterior descending artery in
49%, the left circumflex artery in 9% and the right coronary
artery in 34%. Multiple RWMAs were documented in 6%:
the left anterior descending and right coronary arteries in
3%, the left anterior descending and left circumflex arteries
in 2%, and the left circumflex and right coronary arteries in
1%. In the remaining nine patients (2%), ECG changes
without documentation of RWMAs (because of a poor
echocardiographic window) made the correct diagnosis of
the involved territory of CVS impossible.
In 218 patients, a pharmacological spasm provocation test
during diagnostic coronary angiography in the catheterization
laboratory was also performed several days before or after Erg
Echo, and these data are summarized in Table 1. According to
the coronary angiographic criteria, Erg Echo for the diagnosis
of CVS had a sensitivity of 93% (142 of 152 patients), a
specificity of 91% (60 of 66), a positive predictive value of 96%
(142 of 146), and a negative predictive value of 86% (60 of 70).
The overall accuracy was 93% (202 of 218 patients).
During Erg Echo, transient arrhythmias were observed in
1.9% of the patients (26/1,372). Sinus bradycardia was
recorded in 10 patients, and ventricular premature beats in
another 10, none of which precluded fully successful diag-
nostic testing. Their occurrence did not have any association
with a positive test response. Short-run ventricular tachy-
cardia was observed in two patients. In one patient, it
occurred after the maximum cumulative dose of ergonovine
(0.35 mg) was reached, without any evidence of RWMAs or
ECG changes; in another patient, the tachycardia developed
after intravenous injection of nitroglycerin to reverse
RWMAs of the left anterior descending artery territory.
Atrioventricular block was recorded in four patients with
positive tests showing CVS in the right coronary artery
territory. All of these arrhythmias were transient and
promptly reversed with the administration of nitroglycerin
and nifedipine, as described earlier. There were no compli-
cations, including the development of myocardial infarction,
fatal intractable arrhythmias or strokes. Because all patients
became stable within 10 min after the test, no specific
protocol for serial cardiac enzymes was used.
Among 421 patients with RWMAs on two-dimensional
echocardiography, 34% showed characteristic ST segment
elevation in the simultaneously recorded 12-lead ECG, 11%
showed ST segment depression and another 9% had minor T
wave changes without ST segment displacement. In 46%,
two-dimensional echocardiography detected RWMAs with-
out any ECG changes suggestive of myocardial ischemia.
Clinical impact. Table 2 summarizes the prevalence of
positive test results for Erg Echo according to the clinical
diagnosis. Ergonovine echocardiography was useful for
diagnosing CVS in various clinical settings, including myo-
cardial infarction and aborted sudden cardiac death. For
patients with clinical diagnosis of unstable angina pectoris,
Erg Echo was also useful in documenting the mechanism of
myocardial ischemia if the diagnostic angiography revealed
no evidence of significant fixed disease.
From 1990 to December 1997, a total of 2,033 spasm
provocation tests were performed in either the catheteriza-
tion or echocardiography laboratory. The invasive spasm
provocation test in the catheterization laboratory was the
main method of diagnosing CVS until 1992 and comprised
about 25% of all diagnostic angiographic procedures (Fig.
4A). However, since 1994, noninvasive Erg Echo has
become a more popular diagnostic method—almost replac-
ing invasive coronary angiography and the spasm provoca-
tion test for the last three years (Fig. 4B). In recent days, the
major indications for invasive angiography and spasm prov-
ocation tests for CVS have been poor echocardiographic
window and uncontrolled hypertension.
Among 1,359 completed tests, 33% (453) were done on
an outpatient basis after excluding the possibility of signif-
icant fixed atherosclerosis. The frequency of spasm provo-
cation testing without hospital admission has increased
dramatically (Fig. 5), and in 1997 more than half of the total
number of Erg Echo procedures were requested in the
outpatient clinic. The incidence of positive test response for
Erg Echo did not differ whether it was performed with
(37%, 331/906) or without (20%, 90/453) hospital admis-
sion. The incidence of side effects or arrhythmia during the
procedure also did not differ.
Table 1. Final Results of Ergonovine Echocardiography and





Ergonovine (1) 142 6
Echocardiography (2) 10 60
Sensitivity: 93%; specificity: 91%; (1) predictive value: 96%; (2) predictive value:
86%.
Table 2. Prevalence of Positive Test According to the
Clinical Diagnosis (%)
N (1) %
Variant angina 522 246 47
Non-ischemic chest pain 524 34 6
Unstable angina 233 122 52
Effort angina 48 12 25
Acute myocardial infarction 20 5 25
Old myocardial infarction 8 0 0
Sudden cardiac death 4 2 50
1853JACC Vol. 35, No. 7, 2000 Song et al.
June 2000:1850–6 Ergonovine Echocardiography for Coronary Vasospasm
DISCUSSION
In this study, we have demonstrated that Erg Echo is highly
feasible, with excellent diagnostic sensitivity and specificity
for CVS. Because this test is totally noninvasive and safe, it
can virtually replace invasive coronary angiography with
pharmacological spasm provocation. More frequent and
repeated use of this noninvasive test may contribute to the
possibility of achieving complete differential diagnosis of
chest pain syndrome in routine daily practice.
Comparison with other stress tests. The incidence of
limiting side effects and serious arrhythmias during Erg
Echo was comparable to those studies of other widely
accepted pharmacological stress tests for fixed atherosclero-
sis, such as dobutamine or dipyridamole (19,20). From the
purely echocardiographic point of view, Erg Echo is the
simplest among all kinds of stress tests, as there are no
factors that might degrade the quality of the test, such as
hyperventilation, tachycardia, excessive chest wall move-
ment or significant changes in systemic hemodynamic (14).
Unlike other stress tests for fixed atherosclerotic stenosis of
coronary artery, this test shows a high sensitivity even in
patients with single-vessel spasm; the transmural nature of
supply ischemia resulting from CVS may explain this
difference.
Safety consideration. Spasm provocation testing, under-
taken either in the catheterization laboratory or at bedside,
is a potentially risky and challenging procedure, demanding
a high degree of skill on the part of the operator. Table 3
summarizes the issues regarding the safety of the test.
Although angiographic demonstration of reversible total
occlusion of major epicardial coronary artery is, in itself,
enough for a diagnosis of CVS, moderate vasoconstriction
occurs more frequently in routine provocation testing. In
these cases, other indexes of myocardial ischemia are nec-
essary for a definite diagnosis of CVS. The development of
chest pain or electrocardiographic changes, which are well
known as relatively late events in ischemic cascade, are
classic markers for myocardial ischemia used in the cathe-
terization laboratory (21). The usual 3- to 4-min wait after
each injection of the drug before serial angiography without
sensitive monitoring of ischemic cascade may also contrib-
ute to the potential danger of the procedure. Moreover,
because we cannot predict in which coronary artery territory
the spasm develops, sometimes we spend another several
minutes just switching the angiographic catheters for dem-
onstration of reversible vasoconstriction. All these factors
delay the termination of the vicious cycle of myocardial
ischemia. Considering the fact that the development of
serious arrhythmia or myocardial infarction depends on the
duration of the preceding myocardial ischemia, spasm prov-
ocation testing in the catheterization laboratory is not a safe
procedure at all. Other physicians also pointed out that
injecting a contrast agent into the coronary circulation for
demonstration of reversible vasoconstriction during a severe
ischemic episode may increase the risk involved in the
procedure (22); myocardial imaging rather than angiogra-
phy has been proposed as a more sensitive, more specific and
safer method of identifying CVS (22).
Conventional thinking has held intracoronary injection of
nitroglycerin to be a prerequisite condition for spasm
Figure 4. Temporal changes of frequency of invasive spasm provocation testing in the catheterization laboratory (A) and increased usage
of ergonovine echocardiography (B) for diagnosis of coronary artery spasm.
Figure 5. Temporal changes of frequency of ergonovine echocar-
diography performed in the outpatient clinic without hospital
admission. Solid bar 5 outpatient.
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provocation testing because it may resolve an otherwise
refractory spasm (6,7). However, our data along with other
published investigations (23–25) indicate that this test can
be performed safely with sublingual and intravenous nitro-
glycerin if we can detect the myocardial ischemia resulting
from CVS early.
The most important advantage of Erg Echo is its capacity
to detect RWMAs, which are sensitive and specific markers
of myocardial ischemia, even before the appearance of chest
pain or ECG changes. Our finding, that 46% of patients
diagnosed as having CVS based on development of
RWMAs did not show any ECG changes, reinforces the
importance and superiority of two-dimensional echocardio-
graphic monitoring of ventricular wall motion for safety
during the spasm provocation test. Our data also confirmed
our initial hypothesis that early termination of the vicious
cycle of myocardial ischemia resulting from CVS can be
done safely by early detection of RWMAs. The only
potential risk of Erg Echo is that temporary pacemaker
backup is impossible during the spasm provocation test at
bedside. The incidence of atrioventricular block in our study
was very low, and it reversed promptly with intravenous and
sublingual nitroglycerin. However, multicenter investigation
is needed to determine whether early detection and termi-
nation of myocardial ischemia based on RWMAs can
completely obviate the need for temporary pacemaker
backup.
Study limitations. This is a retrospective analysis of data
obtained in a single center. Clearly, independent confirma-
tion and additional data on the test value would be required.
The clinical usefulness of any noninvasive diagnostic test
depends on the prevalence of the disease; therefore, multi-
center study is necessary to clarify the clinical role of spasm
provocation in routine clinical practice. Because we used
only ergonovine for spasm provocation, it is impossible to
compare our data with other noninvasive spasm provocation
tests such as the hyperventilation test (26,27).
Ergonovine echocardiography can be safely performed
without angiographic demonstration of insignificant fixed
disease if noninvasive exercise ECG or myocardial perfusion
scan shows negative or normal results. In this situation,
because of false negative results of noninvasive stress tests,
some patients with significant fixed disease may have no
occasion for invasive diagnostic angiography until some
adverse clinical event occurs. The safety of omitting invasive
coronary angiography in the differential diagnostic work-up
for patients with chest pain syndrome is, therefore, not
confirmed.
Clinical implications. We have proved that noninvasive
diagnostic test for CVS is feasible and can be done safely in
daily clinical practice; complete work-ups for the differential
diagnosis of chest pain syndromes are possible with Erg
Echo. Even after invasive coronary angiography, a diagnosis
of CVS is not complete, and a repeat angiography with
spasm provocation test is necessary in most cases. With-
drawal of cardioactive drugs for certain periods, potential
risk, and increased catheterization time for a repeat angiog-
raphy and a spasm provocation test have discouraged phy-
sicians from a systematic approach to CVS. Absence of a
reliable and safe noninvasive diagnostic method might
contribute to a physician’s current underestimation of the
clinical importance of CVS.
Another important finding of this study is that Erg
Echo can be used in many different clinical situations to
diagnose CVS. Although variant angina is the most
common clinical diagnosis, patients with CVS also come
to the hospital with clinical diagnoses of unstable angina,
myocardial infarction or even aborted sudden cardiac
death. A considerable number of patients with clinical
presentation of unstable angina pectoris might reveal
near-normal coronary angiograms, and Erg Echo has
demonstrated CVS in some of those patients (28).
Coronary vasospasm is also documented in some patients
with a clinical history of aborted sudden cardiac death
and documented malignant ventricular fibrillation (29).
All these findings confirm the value and clinical useful-
Table 3. Comparison of Potential Advantages and Disadvantages of Ergonovine Echocardiography Versus Invasive Spasm
Provocation Test During Angiography
Advantage Disadvantage
Invasive provocation during angiography Angiogram
Intracoronary nitroglycerin
Temporary pacemaker backup
Relatively late and insensitive ischemic
markers (chest pain,
electrocardiogram changes)
Invasive, perturbing vasomotor tone
Injection contrast agent into coronary
circulation
Continuous monitoring of ischemic
process impossible
Ergonovine echocardiography Regional wall motion abnormalities-sensitive
& specific; early detection and
termination
Noninvasive, not perturbing vasomotor tone
Repeat and follow-up studies




Dependent on acoustic window
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ness of Erg Echo as a noninvasive screening test for CVS
in diverse clinical circumstances.
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